CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Cash Flow-to-Debt Ratio
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Cash Flow-to-Debt Ratio of -1.81x as of December 2025, meaning its operating cash flow of $-2.05 Million could theoretically repay -2% of its total liabilities ($1.13 Million) in one year. Explore long-term investment intensity of CytoMed Therapeutics Limited Ordinary Sh to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CytoMed Therapeutics Limited Ordinary Shares Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. Also explore how large is CytoMed Therapeutics Limited Ordinary Sh's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Year-by-year debt coverage analysis for CytoMed Therapeutics Limited Ordinary Shares. For market capitalisation and broader financial context, see CytoMed Therapeutics Limited Ordinary Sh market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.27x | $-3.70 Million | $1.13 Million | ▼ -23.5% |
| 2024 | -2.65x | $-2.71 Million | $1.02 Million | ▲ +15.7% |
| 2023 | -3.14x | $-3.54 Million | $1.13 Million | ▼ -941.9% |
| 2022 | -0.30x | $-1.40 Million | $4.66 Million | ▲ +38.6% |
| 2021 | -0.49x | $-1.72 Million | $3.50 Million | ▼ -79.2% |
| 2020 | -0.27x | $-916.39K | $3.35 Million | ▲ +56.9% |
| 2019 | -0.64x | $-640.52K | $1.01 Million | — |